Advancing Oncology Care
Treatment Guideline: Inavolisib, Palbociclib, and Fulvestrant for Hormone Receptor-Positive/HER2-negative Metastatic Breast Cancer
Treatment Guideline: Ovarian Function Suppression and Estradiol Monitoring in Early-Stage Estrogen Receptor-Positive Breast Cancer
Tip Sheet: Adrenal Insufficiency in Breast Cancer Patients
AACR Pediatric Special Conference in Cancer Research
Is Subcutaneous Immunotherapy Ready for Prime Time? Join the June 23 webinar
Join Roswell Park Expert at 2nd Annual Upstate Cancer Symposium June 21
Treatment Guideline: Datopotamab Deruxtecan (Dato-DXd) in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer
Treatment Guideline: Contraception in Patients With a History of Breast Cancer
Treatment Guideline: CDK4/6 Inhibitors after Progression on CDK4/6 Inhibitor in Patients With Hormone Receptor-Positive/HER2-negative Advanced Breast Cancer
Treatment Guideline: Capivasertib Plus Fulvestrant for Advanced Estrogen Receptor-Positive Breast Cancer - Updated in 2025
Treatment Guideline: Trastuzumab Deruxtecan (T-DXd) for Metastatic, HER2-Low and HER2-Ultralow Breast Cancer
Treatment Guideline: Patients With a History of Breast Cancer who Desire Pregnancy
Treatment Guideline: Sacituzumab Govitecan for Metastatic, HR-Positive, HER2-Negative Breast Cancer
Treatment Guideline: Elacestrant for Advanced Estrogen Receptor-Positive Breast Cancer
Showing 1 - 15 of 53 results
Previous| 1 | 2 | 3 | 4 |Next
Cancer
Cardiology
Gastroenterology
Neurology
OBGYN
Orthopedics
Pediatrics
BroadcastMed News
Dermatology
Diabetes & Endocrinology
Infectious Diseases
Ophthalmology
Optometry
Otolaryngology
Pulmonology
Surgery
Urology
About
Solutions
Resources
Contact
person Sign In / Create Account
